

Association of Pharmaceutical Manufacturers in Estonia

Riho Tapfer
December 7th

About APME

- Non-profit organization established in **1996**
- Represents **25** manufacturers of research-based original medicinal products and companies manufacturing generic medicines
- CRO-s also members of our association
- Association presents approx. 90% of Estonia's pharmaceutical market turnover
- Member of **EFPIA** (European Federation of Pharmaceutical Industries and Associations)


APME strategic priorities

- The availability of medicines has improved and (comparable to the European average) is in line with international standards
- APME is a sustainable and strong organization and recognized partner

How is our association built up?

- APME has **9 different working groups** such as market access, best practices, medical, regulatory, oncology, vaccine, diabetes, HIV working groups that shape the views represented by the association
- Years ago APME had separate generic WG, but members idea was to keep generic topics as part of all WG-s
- **APME Ethics Committee** - ensures supervision over the activities of pharmaceutical manufacturers in compliance with the Ethical Code
- Generic and R&D companies are on the Supervisory Board by the statute

APME structure



APME representation

Through its Management and Supervisory Board:

- 2014 - 2018 member of Health Insurance Foundation Supervisory Board
- From 2018 in Advisory Committee to the Supervisory Board of the Estonian Health Insurance Foundation
- Healthcare Workstream under umbrella of Estonian Employers Confederation
- Through APME members activities in American Chamber of Commerce
- Estonian Medicines Verification Organisation, founder and leadership on Supervisory Board

Ethical values based on...

- The code of the Association of Pharmaceutical Manufacturers in Estonia on the Promotion of Medicines and Cooperation with Healthcare Professionals
- Covers medicines advertising in medical publications, regulations for sales representatives, and the supply of samples, gifts and hospitality, disclosure of payments etc
- Code for relationship of patient organisations
- Best practice agreement with Estonian Doctors Association

The way we work

1. Contributing with expertise and feedback to legislation, policies and strategy making processes, regular partner for Social Committee of Parliament
2. Organizing roundtables and events (HIV, vaccine, diabetes, oncology etc)
3. Most of APME working groups have own projects engaging authorities, politicians and experts
4. Meetings are scheduled on monthly or annually
5. APME strategical update every year and once after 3 years go through all from the scratch



What is on the table at the moment? (1)

- National Health Development Plan 2020-2030
- Pharmaceutical policy masterplan , made by APME already 2011, new engagement of all stakeholders by MoH
- Health Insurance Fund strategical development plan - focus on cost sharing schemes for medicine, moving toward performance based healthcare
- Managed entry agreements - IT toolbox for cost sharing agreements - 5 years work and cooperation with HIF and other stakeholders



Association of
Pharmaceutical Manufacturers
in Estonia

Positions of the Association of Pharmaceutical Manufacturers in Estonia in developing the national pharmaceutical policy

To ensure the availability
of pharmaceuticals to patients in Estonia
at the European Union average level
by 2015

2011



Association of
Pharmaceutical Manufacturers
in Estonia

What is on the table at the moment? (2)

- Amendments to the legislation on the harmonization of APME ethics code and the Medicinal Products Law
- Implementation of FMD - last days to go live
- Continuing roundtables from Estonian Presidency - oncology, diabetes, HIV etc.
- Availability of medicines - biggest challenge for Estonia (W:A:I:T: indicator)

THANK YOU!

